Drug Trial Radar · NCT06881017
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
Aug 1, 2029
Study completion Nov 1, 2029
Sponsor
- Lead sponsor
- China Medical University, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling (HER2, CLDN18.2, and PD-L1) via next-generation sequencing (NGS) or immunohistochemistry (IHC). Participants will be stratified into distinct molecular subtypes and assigned subtype-specific therapeutic regimens. The primary objectives are to assess treatment efficacy (e.g., objective response rate) and safety profiles across molecularly defined cohorts.
Conditions
- Gastric Cancer
- HER2 + Gastric Cancer
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- PD-L1 Positive
Interventions
TrastuzumabDrug
iv,d1
AdebrelimabDrug
iv,d1,q3w
ApatinibDrug
po,qd,d1-21,q3w
S-1Drug
po,bid,d1-14,q3w
CapecitabineDrug
po,bid,d1-14
OxaliplatinDrug
iv,d1,q3w
zolbetuximabDrug
iv,d1
SHR-A1811Drug
iv,d1 ,q3w
SHR-A1904Drug
iv,d1 ,q3w
SHR-1701Drug
iv,d1 ,q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 2year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.